ARCT · Arcturus Therapeutics Holdings Inc. · Insider Trading

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

The purchase reported on this Form 4 was effected by the Reporting Person pursuant to the Arcturus Therapeutics Holdings Inc. 2020 Employee Stock Purchase Plan (the "ESPP").

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 15, 2025.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

The shares underlying this option vest 25% on December 16, 2025, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

The shares underlying this option vest 25% on December 16, 2025, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

The shares underlying this option vest 25% on December 16, 2025, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

The shares underlying this option vest 25% on December 16, 2025, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Reflects the weighted average price of 12,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on October 15, 2024, with sale prices ranging from $20.03 to $21.12 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the annual grant to the Reporting Person as a member of the Board, prorated based on the date the Reporting Person was appointed to the Board.

Shares underlying the option vest monthly over a two year period from the date of grant. This represents the initial grant to the Reporting Person as a member of the Board of Directors.

Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024.

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

The sales reported on this Form 4 were effected in open market transactions by the Reporting Person.

Reflects the weighted average price of 50,000 shares of common stock of Arcturus Therapeutics Holdings Inc. (the "Issuer") sold by the Reporting Person in multiple transactions on June 12, 2024, with sales prices ranging from $31.52 to $33.54 per share. The Reporting Person undertakes to provide, upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Reflects the price of 114 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person on June 5, 2024. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Reflects the weighted average price of 26,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on June 3, 2024, with sale prices ranging from $40.00 to $40.325 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Reflects the weighted average price of 17,435 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on March 25, 2024, with sale prices ranging from $35.00 to $35.045 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Reflects the weighted average price of 8,565 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on March 19, 2024, with sale prices ranging from $35.00 to $35.02 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.